RecruitingPhase 4NCT06465641

Methylphenidate in KBG Syndrome: N-of-1 Series

Effectiveness of Methylphenidate in Children and Adolescents With KBG Syndrome: An N-of-1 Series


Sponsor

Radboud University Medical Center

Enrollment

15 participants

Start Date

Nov 13, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial\] is to learn about the effect of methylphenidate in children and adolescents with KBG syndrome. The main question it aims to answer is: • What is the effectiveness of methylphenidate on attention deficit and ADHD-related symptoms in children and adolescents with KBG syndrome? Participants will receive multiple blocks of treatment with methylphenidate and placebo and fill out various questionnaires.


Eligibility

Min Age: 6 YearsMax Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Methylphenidate Hydrochloride and a drug called Placebo for people with adhd - combined type and kbg syndrome. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethylphenidate Hydrochloride

Methylphenidate hydrochloride in capsules

DRUGPlacebo

Microcrystalline cellulose in capsules


Locations(1)

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06465641


Related Trials